Literature DB >> 12935781

Anti-apoptotic effects of CNTF gene transfer on photoreceptor degeneration in experimental antibody-induced retinopathy.

Grazyna Adamus1, Brad Sugden, Sharon Shiraga, Adrian M Timmers, William W Hauswirth.   

Abstract

Autoantibodies against recoverin are found in the sera of patients with cancer-associated retinopathy syndrome, a paraneoplastic disease associated with retinal degeneration. We have previously shown that anti-recoverin autoantibodies induced photoreceptor apoptotic cell death after injection into the vitreous of Lewis rats. Ciliary neurotrophic factor (CNTF) has been shown to promote the survival of a number of neuronal cell types, including photoreceptors. In this study, we examined whether an adeno-associated virus (AAV)-mediated delivery of gene encoding the human CNTF protected photoreceptor cells from anti-recoverin antibody-induced death. One month after subretinal injection of the AAV-CNTF gene into one eye and a control vector into the other eye, an anti-recoverin antibody was injected to induce retinal cell death in Lewis rats. Subretinal administration of the virus led to an efficient transduction of photoreceptors, as indicated by immunostaining of retinas with anti-CNTF. Histological examination of the corresponding retinas showed that photoreceptor cells were significantly protected from apoptotic death in the CNTF-treated eyes. CNTF treatment of the retinas resulted in a time-dependent activation of STAT 3. The present study shows that an AAV-mediated delivery of CNTF may protect photoreceptors from antibody-induced cell death through the activation of STAT3 and the suppression of caspase 3 activity, a key caspase leading to apoptosis. Thus, CNTF may be a useful treatment for human antibody-mediated retinal degeneration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12935781     DOI: 10.1016/s0896-8411(03)00092-1

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  8 in total

1.  Expression profiling of p53-target genes in copper-mediated neuronal apoptosis.

Authors:  Jacob W Vanlandingham; Nadine M Tassabehji; Rikki C Somers; Cathy W Levenson
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

2.  Retinal gene therapy using adeno-associated viral vectors: multiple applications for a small virus.

Authors:  William W Hauswirth
Journal:  Hum Gene Ther       Date:  2014-08       Impact factor: 5.695

3.  Molecular and cellular alterations induced by sustained expression of ciliary neurotrophic factor in a mouse model of retinitis pigmentosa.

Authors:  Kun Do Rhee; Alberto Ruiz; Jacque L Duncan; William W Hauswirth; Matthew M Lavail; Dean Bok; Xian-Jie Yang
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-03       Impact factor: 4.799

4.  Effect of CNTF on retinal ganglion cell survival in experimental glaucoma.

Authors:  Mary Ellen Pease; Donald J Zack; Cynthia Berlinicke; Kristen Bloom; Frances Cone; Yuxia Wang; Ronald L Klein; William W Hauswirth; Harry A Quigley
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-05       Impact factor: 4.799

5.  Paraneoplastic Retinopathy/Optic Neuropathy.

Authors:  Denise M Damek
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

6.  Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70.

Authors:  Thimmappa S Anekonda; Grazyna Adamus
Journal:  BMC Res Notes       Date:  2008-12-01

7.  Recent advances in pharmacotherapy of glaucoma.

Authors:  S K Gupta; Galpalli Niranjan D; S S Agrawal; Sushma Srivastava; Rohit Saxena
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

8.  Endothelin-2-mediated protection of mutant photoreceptors in inherited photoreceptor degeneration.

Authors:  Alexa N Bramall; Michael J Szego; Laura R Pacione; Inik Chang; Eduardo Diez; Pedro D'Orleans-Juste; Duncan J Stewart; William W Hauswirth; Masashi Yanagisawa; Roderick R McInnes
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.